PTC Therapeutics discontinues development of ALS drug after trial failure
Adds background in paragraphs 2, 5, trial details in paragraph 4, updates share move
Nov 26 (Reuters) -PTC Therapeutics PTCT.O said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it failed to slow disease progression in a mid-stage trial.
This marks the latest setback in a long list of roadblocks on the path to developing effective treatments against amyotrophic lateral sclerosis (ALS), a condition that affects 16,000 to 32,000 people in the United States and almost completely paralyzed late British physicist Stephen Hawking.
PTC Therapeutics' drug, utreloxastat, was tested in patients with ALS, a rare neurological disease that can break down nerve cells in the brain and spinal cord responsible for muscle movements.
The company said the oral drug also failed to meet statistical significance in the trial's secondary goals.
Japanese firm Mitsubishi Tanabe's Radicava, generic drug Riluzole, and Biogen's BIIB.O Qalsody are some of the FDA approved ALS treatments available in the U.S.
Shares of New Jersey-based PTC Therapeutics fell 2.6% to $44.80 after the bell.
Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
